Kura Oncology, Inc.

KURA · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders1.4%

Institutions99.6%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$67.48M	$53.88M	–	–	–	–	–	–	–	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$303.63M	-$193.19M	–	–	–	–	–	–	–	–
Operating income as a percentage of revenue.	-449.9%	-358.5%	–	–	–	–	–	–	–	–
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$278.67M	-$173.98M	-$135.84M	-$130.47M	-$89.63M	-$63.14M	-$60.45M	-$35.43M	-$27.56M	-$22.63M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-3.00	$-2.00	$-2.00	$-1.97	$-1.69	$-1.51	$-1.00	$-1.00	$-1.00	$-2.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-3.00	$-2.00	$-2.00	–	–	–	–	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$149.10M	$224.46M	$51.80M	$90.67M	$325.49M	$26.14M	$16.12M	$11.43M	$9.72M	$15.44M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$738.36M	$760.16M	$456.31M	$534.05M	–	$241.97M	$182.38M	$95.85M	$69.82M	$87.26M
All of the company's interest-bearing borrowings, short and long term combined.	$9.71M	$9.52M	$9.16M	–	$7.25M	$7.50M	$7.50M	$7.10M	$7.32M	–
Everything the company owes — debt, unpaid bills, and other obligations.	$564.23M	$346.52M	$36.03M	$27.44M	–	$23.19M	$21.39M	$15.99M	$12.95M	$5.16M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$174.13M	$413.64M	$420.28M	$506.61M	–	$218.78M	$160.99M	$79.86M	$56.88M	-$26.30M

Cash Flow Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$64.06M	$134.32M	-$110.06M	-$104.55M	-$69.83M	-$54.76M	-$48.66M	-$28.44M	-$25.35M	-$17.93M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$6.64M	$472000	$626000	$1.15M	$2.17M	–	–	–	–	$64000
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$70.70M	$133.84M	-$110.69M	-$105.70M	-$72.00M	–	–	–	–	-$17.99M

	You	Peer avg
Revenue Growth	+36.5%	-61.3%
ROE	-167.7%	-29.6%

Kura Oncology, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison